Sattar N, McGuire DK, Pavo I, et al
An analysis of the market share for various GLP-1 drugs targeting diabetes revealed a significant in sales revenue for Semaglutide (from 2022 to 2023) and Dulaglutide (from 2021 to 2023)
Type 2 Diabetes Focus Tirzepatide Tirzepatide has 5 SURPASS T2D trials, FDA approval for diabetes (Mounjaro), and demonstrated superiority over semaglutide in SURPASS-2
New prescriptions require a scheduled consultation with a One Medical provider either in-person or via a scheduled video appointment
Meanwhile, overall aging indicators were significantly improved: locomotor activity and endurance were enhanced, hair gloss increased, levels of aging-related inflammatory factors (such as TNF-, IL-6) decreased, and the average lifespan of mice was prolonged